Description
Epitalon, also known as Epithalamin, is a synthetic peptide derived from the naturally occurring pineal peptide, which plays a key role in regulating the circadian rhythm and promoting longevity. Epitalon is primarily studied for its potential to extend lifespan, improve cellular regeneration, and counteract the effects of aging. It is most commonly researched for its effects on telomere maintenance, oxidative stress reduction, and overall longevity.
Epitalon works by stimulating the production of telomerase, an enzyme that helps preserve the length of telomeres, which naturally shorten as cells divide. This action may help delay the aging process, reduce cellular damage, and promote the repair of damaged DNA. Researchers have also investigated Epitalon for its potential to enhance immune function, regulate sleep patterns, and improve overall vitality in aging populations, making it a valuable tool in studies related to aging and age-related diseases.
The 10mg vial of Epitalon is ideal for researchers beginning studies on aging, cellular regeneration, and telomere maintenance. This vial size is suitable for in vitro studies, receptor binding assays, and early in vivo experiments in animal models, providing enough material for focused research without requiring larger quantities.
Progression Peptides offers Epitalon as a high-purity lyophilized powder, with third-party purity verification to ensure consistency and reliability in research. The lyophilized form preserves the peptideâs stability and bioactivity when handled and stored according to recommended guidelines.
Reconstitution: Reconstitute with bacteriostatic water, allowing it to dissolve gently without agitation. The solution should remain clear and free from visible particles.
Storage: Store the lyophilized peptide at -20°C. Once reconstituted, refrigerate at 2-8°C and use within 30 days.
For research purposes only. Not for human consumption or veterinary use. Sold exclusively for laboratory and in vitro research.






Reviews
There are no reviews yet.